Diabetic retinopathy (DR) is a leading cause of blindness globally.
1,2 Disease severity ranges from nonproliferative DR (NPDR) to proliferative DR (PDR), with 13 distinct categories on the Diabetic Retinopathy Severity Scale (DRSS) developed in the Early Treatment Diabetic Retinopathy Study (ETDRS).
3 The microvascular ischemia associated with DR leads to vision loss, primarily through pathologic neovascularization of the retina and/or anterior segment and diabetic macular edema (DME). Increasing NPDR severity is associated with an increased risk of progression to PDR and vision loss.
3